Biora Therapeutics Stock Forum

$Biora Therapeutics (BIOR.US)$  is selling off like they just announced they were in bed with child organ harvesters. No news, so what gives?

$Biora Therapeutics (BIOR.US)$
Biora Therapeutics Announces Positive Nasdaq Listing Decision
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements.
"We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their...

$Biora Therapeutics (BIOR.US)$ Anticipated Milestones
NaviCap™ Targeted Oral Delivery Platform and BT-600 in ulcerative colitis
Biora will present Phase 1 clinical trial data from the BT-600 program at the American College of Gastroenterology annual meeting in October, 2024.
Initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024.
BioJet™ Systemic Oral Delive...

$Biora Therapeutics (BIOR.US)$
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...

$Biora Therapeutics (BIOR.US)$
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...

$Biora Therapeutics (BIOR.US)$ Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives